Related Experiment Video
Updated: Feb 5, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
[Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer]
Peng Song1, Li Zhang1, Congcong Shang1
1Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China.
Abstract:
The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug resistance after treatment. This article has been explained separately from the ALK genetic background, the detection method, the treatment of the three generations of ALK inhibitors and the strategy after drug resistance. It is desire to have reference value and reference meaning for clinical work. .
Insights
Anaplastic Lymphoma Kinase (ALK) gene rearrangements occur in 3-5% of non-small cell lung cancer (NSCLC) patients. While ALK inhibitors extend survival, acquired drug resistance remains a challenge, necessitating new treatment strategies.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Anaplastic Lymphoma Kinase (ALK) gene rearrangements are found in 3-5% of non-small cell lung cancer (NSCLC) cases.
- ALK inhibitors have significantly improved outcomes for patients with advanced ALK-positive NSCLC.
- Acquired drug resistance is a major limitation in long-term treatment efficacy.
Purpose of the Study:
- To provide a comprehensive overview of ALK gene rearrangements in NSCLC.
- To discuss the evolution and application of ALK inhibitors.
- To explore strategies for overcoming acquired resistance to ALK-targeted therapies.
Main Methods:
- Review of current literature on ALK gene rearrangements and inhibitors.
- Analysis of ALK detection methods.
- Discussion of treatment paradigms for successive generations of ALK inhibitors.
- Exploration of resistance mechanisms and clinical strategies.
Main Results:
- ALK gene rearrangements are a key driver in a subset of NSCLC.
- Multiple generations of ALK inhibitors offer improved efficacy and toxicity profiles.
- Understanding resistance mechanisms is crucial for developing effective treatment strategies.
Conclusions:
- ALK-targeted therapy has transformed the treatment landscape for ALK-positive NSCLC.
- Continued research into resistance mechanisms and novel therapeutic approaches is essential.
- This review offers valuable insights for clinical decision-making in managing ALK-positive NSCLC.
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Lung Capacity
Marcia's Theory of Identity Status
Receptor Tyrosine Kinases
Electrical Current

